% IMPORTANT: The following is UTF-8 encoded. This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.
@ARTICLE{Eggers:850854,
author = {Eggers, Carsten and Dano, Richard and Schill, Juliane and
Fink, Gereon R. and Timmermann, Lars and Voltz, Raymond and
Golla, Heidrun and Lorenzl, Stefan},
title = {{A}ccess to {E}nd-of {L}ife {P}arkinson's {D}isease
{P}atients {T}hrough {P}atient-{C}entered {I}ntegrated
{H}ealthcare},
journal = {Frontiers in neurology},
volume = {9},
issn = {1664-2295},
address = {Lausanne},
publisher = {Frontiers Research Foundation},
reportid = {FZJ-2018-04614},
pages = {627},
year = {2018},
abstract = {Background: Palliative care in Parkinson's Disease (PD)
patients considerably differs from palliative care in
oncology patients. Integrated care models are a concept to
support patients and improve management of PD symptoms.
However, it is not known if the access to PD patients at the
end of life can be achieved through integrated care
models.Aim: To analyze an integrated model of care for PD
patients with the aim to identify if this integrated model
of care has access to PD patients at the end of
life.Material and Methods: The Cologne Parkinson's network
was designed as a randomized, controlled prospective
clinical trial in order to increase quality of life of PD
patients. This innovative model of care integrated a
neurologist in private practice, a movement disorder
specialist of the University Hospital and a PD nurse.
Mortality rates of PD patients during the study period of 6
months were registered and compared with mortality rates of
the general population of Germany according to the Federal
Statistical Office of Germany. The retrospective post-hoc
analysis was conducted after completion of the initial study
at the University Hospital and neurologists' practices in
the greater area of Cologne, Germany. Eligible patients had
a diagnosis of idiopathic PD and were aged 25–85
years.Results: Parkinson's Disease patients in this trial
had an even slightly lower mortality rate as the general
population (1.66 v. $2.1\%).$ These results are
contradictory and speak for a substantial proportion of
late-stage disease patients, who have not been adequately
included in this study or have been better treated within
this trial. The mean disease duration of patients in this
study was around 6 years which resembles the lower range of
the mean disease duration at death of PD patients in
generalConclusions: The results of our post-hoc analysis
show, that accessing PD patients in the last phase of their
disease is extremely difficult and nearly fails in spite of
an integrated care approach. Reasons for poor access and
loss of follow-up at the end of life have to be identified
and care models for PD patients until the end of life should
be developed urgently.},
cin = {INM-3},
ddc = {610},
cid = {I:(DE-Juel1)INM-3-20090406},
pnm = {572 - (Dys-)function and Plasticity (POF3-572)},
pid = {G:(DE-HGF)POF3-572},
typ = {PUB:(DE-HGF)16},
UT = {WOS:000440198900001},
pubmed = {pmid:30105000},
doi = {10.3389/fneur.2018.00627},
url = {https://juser.fz-juelich.de/record/850854},
}